Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 1:22:1079-84.
doi: 10.12659/msm.895245.

Over-Expression of CD200 Predicts Poor Prognosis in Cutaneous Squamous Cell Carcinoma

Li Li  1 , YanLi Tian  2 , ChengFang Shi  2 , Hua Zhang  1 , Zhi Zhou  1
Affiliations

Over-Expression of CD200 Predicts Poor Prognosis in Cutaneous Squamous Cell Carcinoma

Li Li et al. Med Sci Monit. .

Abstract

Background: CD200 is reported to be involved in tumor progression and can serve as a prognostic marker in several cancers. The purpose of this study was to evaluate the prognostic significance of CD200 in cutaneous squamous cell carcinoma (CSCC).

Material/methods: The relative mRNA and protein expression of CD200 in the tumor tissues and corresponding normal tissues of 102 CSCC patients were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot analysis, respectively. The chi-square test was used to analyze the association between CD200 expression and clinical features of CSCC patients. In addition, the overall survival of the patients according to the expression level of CD200 was estimated by Kaplan-Meier analysis and the prognostic significance of the gene was analyzed by Cox regression analysis.

Results: Increased expression of CD200 was detected in the tumor tissues compared with the corresponding normal tissues both at mRNA and protein level. And CD200 expression level was associated with tumor differentiation grade (P=0.041) and clinical stage (P=0.004). Patients with high expression level of CD200 had a shorter overall survival than those with low expression (31.3 months vs. 41.9 months) and there was a significant difference between them (log-rank test, P<0.001). Cox regression analysis indicated that CD200 could be an independent marker for the prognosis of CSCC.

Conclusions: CD200 is up-regulated and may be a novel biomarker for the prognosis in CSCC, and it may be a potential therapeutic target for CSCC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative mRNA expression of CD200 in tumor tissues and corresponding normal tissues of CSCC patients (GAPDH as normalized control). CD200 expression was higher in tumor tissues than in adjacent normal tissues (P<0.001).
Figure 2
Figure 2
Relative protein expression of CD200 in tumor tissues and corresponding normal tissues of CSCC patients. CD200 protein expression was higher in tumor tissues than in adjacent normal tissues (P<0.001).
Figure 3
Figure 3
Overall survival of CSCC patients according to the expression of CD200. Patients with high level of CD200 had a shorter overall survival time than those with low-expression. There was a significant difference between the groups (log-rank test, P<0.001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;26(1):1–26. - PubMed
    1. Chen MK, Cai MY, Luo RZ, et al. Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. Br J Dermatol. 2015;172(1):111–19. - PubMed
    1. Martorell-Calatayud A, Sanmartin Jimenez O, Cruz Mojarrieta J, Guillen Barona C. Cutaneous squamous cell carcinoma: defining the high-risk variant. Actas Dermosifiliogr. 2013;104(5):367–79. - PubMed
    1. Cerroni L. Cutaneous squamous-cell carcinoma. New Engl J Med. 2001;345(4):296. author reply 296–97. - PubMed
    1. Yanofsky VR, Mercer SE, Phelps RG. Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer. 2011;2011:210813. - PMC - PubMed